Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Five Below Inc (FIVE) vs Smith & Nephew plc (SNN) Price & Performance

Five Below IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Five Below Inc vs Smith & Nephew plc — how do they compare? Five Below Inc trades at $200.21 (market cap $10.67B), while Smith & Nephew plc trades at $31.43 (market cap $12.81B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Smith & Nephew plc pays a 2.54% dividend while Five Below Inc pays none. Which is the better fit depends on your goals.

FIVESNN
Market Cap
$10.67B$12.81B
Sector
Consumer StaplesHealth
52-Week High
$247.71$38.70
52-Week Low
$131.94$28.73
Enterprise Value
$11.56B$15.58B
Dividend Yield
2.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Five Below Inc

Five Below (FIVE) trades at $193.11, up 0.82% with a bullish technical signal despite mixed moving averages. The company demonstrates strong growth with revenue reaching $3.88 billion in 2025 and consistent earnings beats, including Q1 2026 EPS of $2.22 beating expectations of $1.77. Valuation metrics show a P/E of 24.34 and P/S of 2.11, while profitability remains solid with 8.67% net margin and 21.13% ROE. Recent news highlights store expansion to 2,000 locations and strategic investments in digital marketing.

FIVE presents a compelling growth story with analyst consensus pointing to 33% upside potential to $252.09 target. The stock benefits from strong institutional support (60% buy ratings) and positive earnings momentum, though investors should monitor competitive pressures in value retail and the sustainability of expansion-driven cash flow patterns. Current technical levels show support at $191 with resistance at $194.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.

Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.

Returns comparison

Trailing returns across standard periods

About Five Below Inc

Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics

Read more on FIVE

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN